Skip to content

Corneal Crosslinking Treatment Study

Prospective Randomised Corneal Crosslinking Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04427956
Enrollment
54
Registered
2020-06-11
Start date
2017-05-23
Completion date
2024-11-19
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive Keratoconus

Keywords

corneal crosslinking

Brief summary

Three different protocols for inducing corneal crosslinks in subjets with progressive keratoconus will be evaluated in this randomised clinical study.

Detailed description

Riboflavin does not penetrate the intact corneal epithelium. Corneal cross linking (CXL) is typically performed using the so-called Dresden protocol. The Dresden protocol states 30 minutes of UVA-radiation (3mW/cm2) but a 10 minute irradiation protocol (9mW/cm2) is frequently used. Both of the protocols involve mechanical removal of the epithelium over the central 8 mm of the corneal surface. The first days after treatment therefore involves some degree of pain, often intense, and the presence of a healing epithelial defect may be associated with development of infiltrates in the cornea. A number of approaches have been evaluated in order to promote riboflavin penetration through the intact epithelium, of which iontophoresis appears most promising. Keratoconic corneas are thin at the cone location and sometimes it is difficult to maintain the safety margin of 400 microns during corneal crosslinking. Instead of using isotonic standard riboflavin, a swelling effect of the cornea can be obtained by using hypotonic riboflavin. However, the latter has been indicated as less effective in the process of inducing cross links. Eighty-one of 81 patients of various degrees of keratoconus will be randomised to one of the following groups: 1) CXL (UVA 9mW/cm2) using isotonic riboflavin, or 2) CXL (UVA 9mW/cm2) using hypotonic riboflavin or 3) Iontophoresis with Ricrolin with following CXL (UVA 9mW/cm2). Hypothesis: i) CXL with hypotonic riboflavin or CXL with Ricrolin administered by iontophoresis or CXL with isotonic riboflavin is non-inferior compared to standard CXL with isotonic riboflavin. ii) The morphological structure post-CXL in the three different groups will be similar without any significant differences. The iontophoresis-assisted treatment arm has been interrupted due to low efficacy in halting disease progression. The results have been published.

Interventions

PROCEDURECorneal crosslinking: CXL (UVA 9mW/cm2)

CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.

CXL protocol with isotonic riboflavin

CXL protocol with hypotonic riboflavin

PROCEDUREIontophoresis

CXL protocol with iontophoresis and ricrolin

Sponsors

Region Skane
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective randomized interventional clinical trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Progress in keratoconic eye. We define progress as an increase in Kmax of 1.0 diopter in 1 year or 0.5 diopter in 6 months. This increase in Kmax will be accepted as progression if concomitant changes tomographic parameters.

Exclusion criteria

* Concurrent ocular infection or corneal disease other than keratoconus. * Pregnancy. * Treatment with Isotretinoin.

Design outcomes

Primary

MeasureTime frameDescription
Postoperative change in visual acuityPatients will be evaluated 1, 6, 12 and 24 months after treatment.Uncorrected visual acuity (UCVA) and best spectacle corrected visual acuity (BSCVA)
Postoperative change in KmaxPatients will be evaluated 1, 6, 12 and 24 months after treatment.Maximum corneal steepness

Secondary

MeasureTime frameDescription
Postoperative change in Keratocyte cell densityConfocal microscopy will be performed at 6 and 12 months.Keratocyte cell density will be evaluated using confocal microscopy
Postoperative change in endothelial cell countConfocal microscopy will be performed at 6 and 12 months.Endothelial cell count will be evaluated using confocal microscopy
Postoperative change in astigmatismPatients will be evaluated 1, 6, 12 and 24 months after treatment.Corneal astigmatism
Postoperative change in the corneal thickness during CXL treatmentCorneal pachymetry will be evaluated before and then every 5 minutes during 30 minutes under CXL treatment.Corneal pachymetry is the process of measuring the thickness of the cornea
Postoperative change in demarcation linesConfocal microscopy will be performed at 6 and 12 months.Identification of the demarcation lines with confocal microscopy will help establishing how deep was the effect of the CXL treatment.
postoperative change in corneal nerve cell densityConfocal microscopy will be performed at 6 and 12 months.Corneal nerve cell density will be evaluated using confocal microscopy

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026